

**SUMMIT MEDICAL GROUP CANCER CENTER IS AMONG FIRST IN U.S.  
TO OFFER THE DUETTE STUDY: A CLINICAL RESEARCH STUDY FOR WOMEN  
WITH RELAPSED OVARIAN CANCER**

FLORHAM PARK, NJ – SEPTEMBER 24, 2020 – Offering novel treatment options to patients through clinical research, [Summit Medical Group](#) today announced its [Cancer Center](#) is among the first U.S. sites to offer the [DUETTE Study](#), a Phase II, randomized, multicenter study in women with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received PARP inhibitor maintenance treatment.

PARP inhibitors (or poly-ADP ribose polymerase) are a class of targeted agents for the treatment of solid tumors. Currently, PARP inhibitors such as olaparib, which improve progression-free survival, are approved by the Food and Drug Administration (FDA) for the treatment of ovarian cancers. These agents have provided significant benefit in prolonging survival, but it remains uncertain how women whose disease recurs more than six months after their last dose of chemotherapy (platinum-sensitive) should be treated.

The aim of the DUETTE Study, sponsored by AstraZeneca, is to investigate whether olaparib, when given as a second maintenance treatment (monotherapy or combination therapy with ceralasertib), improves progression-free survival compared to placebo in these women.

“The DUETTE study is critically important in enabling us to determine the best way to treat women with recurrent ovarian cancer and improve survival,” says Darlene Gibbon, MD, Principal Investigator of the DUETTE Study and the Director of Gynecologic Oncology at Summit Medical Group Cancer Center. “We are thrilled to be one of the first facilities to offer this trial to patients in the United States. It’s a testament to the strength and resilience of our cancer center and clinical trials program, which carried on steadfastly despite the COVID-19 pandemic.”

**Study Eligibility**

Approximately 192 participants will be recruited from 120 study sites worldwide. Qualifying criteria include, but are not limited to the following:

- Female, aged 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 within 28 days of randomization
- Diagnosis of high-grade epithelial ovarian cancer with disease relapse on or after completion of PARP inhibitor maintenance therapy AND have not received any intervening systemic treatment (excluding platinum-based chemotherapy during Screening Part 1) since discontinuation of PARP inhibitor therapy
- Received a minimum of 6 months of prior PARP inhibitor treatment received in the maintenance setting for PSR ovarian cancer (a minimum of 12 months is required if the patient received PARP inhibitor maintenance following first line chemotherapy). If the prior PARP inhibitor used was olaparib then patients must have received treatment without significant toxicity or the need for a permanent dose reduction
- Platinum-sensitive disease at the time of disease relapse
- Are postmenopausal or have evidence of non-childbearing status (for women of childbearing potential)

Participants will receive standard of care platinum-based chemotherapy and then be randomized to one of three possible arms (64 participants per arm):

- olaparib (PARP inhibitor) alone
- olaparib and ceralasertib (ATR inhibitor) in combination
- a placebo

Prospective participants who would like more information on the DUETTE Study and their eligibility to participate may contact Summit Medical Group Oncology Trials at 973-436-1755 or visit the [Gynecologic Oncology Clinical Trials web page](#).

All active clinical research and trials offered by Summit Medical Group can be found [here](#).

### **About Summit Medical Group**

[Summit Medical Group](#) (SMG) is one of the largest independent physician organizations in the country and the premier multispecialty medical practice in New Jersey. With more than 900 providers and 80 medical specialties and services, SMG offers exceptional patient care, the finest comprehensive medical services, state-of-the-art diagnostics and technologies, and leading-edge treatments. Through its merger with [CityMD](#), the leading urgent care provider in the New York metro area, SMG provides patients a full spectrum of high-quality primary, specialty and urgent care.

[Summit Medical Group Cancer Center](#) provides world-class cancer services to patients in northern New Jersey and the tri-state area. By offering a fully integrated multidisciplinary cancer center, patients have access to specialists and services across the entire cancer care spectrum to support them from diagnosis to survivorship.

For more information, visit [SummitMedicalGroup.com](http://SummitMedicalGroup.com).